Shenzhen Chipscreen Biosciences-A

Shenzhen Chipscreen Biosciences (688321.CH) - Risks Outweigh Opportunities

Equity Bottom-Up
133 Views, 18 Jan 2022 09:00
EXECUTIVE SUMMARY
  • The small market space of peripheral T-cell lymphoma indication and the fierce market competition of other indications, products and candidates make the Company’s future commercialization performance uncertain. 
  • The continuous large investment in R&D, high selling expenses, and declining R&D expending capitalization would further drag down profitability.
  • So, our view is that we are conservative about Chipscreen Biosciences’s outlook at the current stage.
detail (5-minute read)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
logo
Logo
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)

Over 13 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in ... 

Zoom:
NaN%
x